Abstract 3194: Opposing roles of product CD27 and TIGIT expression in outcome to CAR-T cell therapy in R/R LBCL
Justin A. Budka(Gilead Sciences (United Kingdom)), Simone Filosto(Kite (United States)), Mike Mattie, Soumya Poddar(University of California, Los Angeles), Subing Cao, Yohei Arihara(Sapporo Medical University), Yusuke Kamihara(Sapporo Medical University), Chad M. Williams, Saran Vardhanabhuti, Davide Bedognetti(Sidra Medical and Research Center), Gabriela Balderrama-Gutierrez(University of California, Irvine), Jerome Ritz(Dana-Farber Cancer Institute), Shogo Miura(Dana-Farber Cancer Institute), Jaeyeon Kim(Sidney Kimmel Cancer Center)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k